Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290292 (2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290292 (2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 10 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290334 (9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290336 (10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290334 (9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290336 (10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 11 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290286 (7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290309 ((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290314 (10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290320 (10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290324 (4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290286 (7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290309 ((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290314 (10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290320 (10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290324 (4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 13 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290307 ((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290312 (4-(Piperidin-4-yl)-10-[4-(trifluoromethyl)phenyl]p...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290313 (10-Phenyl-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290269 (10-Bromo-4-(piperidin-4-yl)pyrimido[1,2-b]indazol-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290329 (10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290307 ((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290312 (4-(Piperidin-4-yl)-10-[4-(trifluoromethyl)phenyl]p...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290313 (10-Phenyl-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290269 (10-Bromo-4-(piperidin-4-yl)pyrimido[1,2-b]indazol-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290329 (10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 14 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290308 ((−)-trans-4-(2-Methylpiperidin-4-yl)-10-phen...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290343 (10-(1-Methyl-1H-pyrazol-5-yl)-4-(piperidin-4-yl)py...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290315 (4-(Piperidin-4-yl)-10-(pyridin-3-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290262 (10-Chloro-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290328 (10-Bromo-7-fluoro-4-(piperidin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290331 (10-Bromo-9-methyl-4-(piperidin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290333 (10-Isopropoxy-4-(piperidin-4-yl)pyrimido[1,2-b]ind...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290335 (10-(2,6-Difluorophenyl)-4-(piperidin-4-yl)pyrimido...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290343 (10-(1-Methyl-1H-pyrazol-5-yl)-4-(piperidin-4-yl)py...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290308 ((−)-trans-4-(2-Methylpiperidin-4-yl)-10-phen...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290311 (10-(4-Methoxyphenyl)-4-(piperidin-4-yl)pyrimido[1,...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290315 (4-(Piperidin-4-yl)-10-(pyridin-3-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290262 (10-Chloro-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290328 (10-Bromo-7-fluoro-4-(piperidin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290331 (10-Bromo-9-methyl-4-(piperidin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290333 (10-Isopropoxy-4-(piperidin-4-yl)pyrimido[1,2-b]ind...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290335 (10-(2,6-Difluorophenyl)-4-(piperidin-4-yl)pyrimido...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290311 (10-(4-Methoxyphenyl)-4-(piperidin-4-yl)pyrimido[1,...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 15 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290316 (4-(Piperidin-4-yl)-10-(pyridin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290332 (10-Bromo-7-methyl-4-(piperidin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290338 (10-Bromo-8-fluoro-4-(piperidin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290316 (4-(Piperidin-4-yl)-10-(pyridin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290332 (10-Bromo-7-methyl-4-(piperidin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | n/a | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel... | US Patent US10668071 (2020) BindingDB Entry DOI: 10.7270/Q2KP8554 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Plasminogen [101-181] (Homo sapiens (Human)) | BDBM290338 (10-Bromo-8-fluoro-4-(piperidin-4-yl)pyrimido[1,2-b...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 16 | n/a | n/a | n/a | n/a | 7.0 | n/a |
BAYER PHARMA AKTIENGESELLSCHAFT US Patent | Assay Description The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall... | US Patent US10098883 (2018) BindingDB Entry DOI: 10.7270/Q2G73GSM | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 210 total ) | Next | Last >> |